

BRIEFING ON HOSPITAL SERVICES OUTSOURCING PROGRAMME & REQUEST FOR PROPOSAL

25 JULY 2024



HOSPITAL SERVICES OUTSOURCING PROGRAMME (HSOP) INTRODUCTION

Private Hospitals, Hospital Tentera & Hospital Pengajaran University (HPU)

BACKGROUND

- RM144,000,000 has been allocated to outsource hospital services to private hospitals.
- The objectives of outsourcing are:
 - 1. Reduced Waiting Time (of elective cases) 90%
 - 2. Decongestion (of wards/emergency departments) 5%
 - **3. Others** (ad hoc outsourcing) **5%**
- To start with high volume, high value (optimise value-for-money)
 - Cardiothoracic (Coronary Arteries Bypass Graph)
 - Cardiology (Investigations, Diagnosis, Interventions)
 - Imaging/Radiology (Ultrasound, CT Scan, MRI Scan)
 - Nephrology (Arteriovenous Fistula Surgery)
 - Nuclear Medicine (PET Scan)

NOTE: May shift to other services if not receiving satisfactory support/offers from private/university hospitals.



TIMELINE FOR IMPLEMENTATION

Planning phase

- Gathering and analysing important data
- Getting mandate to implement
- Working out together with KKM strategies for outsourcing
- Identifying resources need for implementation
- Preparing proposals of roll out plans
- Identifying potential providers

Roll out

Q3-Q4

2024


- Start outsourcing cases to private providers
- Monitoring of the outsourcing program
- Managing incoming risks
- Start claims data collection
- Managing provider and patient feedbacks
- More negotiations & contracting if needed

Q2 2024

- Onboarding more providers if needed
- Improvements of IT systems

Expansion

- Expansion of hospital services outsourcing
- Application of innovative payment mechanism





Development & Preparation

Q1 2024

- Setting up implementation team
- Stakeholder engagements
- Expanding DT System to incorporate Casemix parameters and hospital services module
- Developing fee schedule and payment mechanisms
- Developing quality and risks monitoring for the whole program
- Finalising Outsourcing pathway including patient pathway
- Request of Proposals & Market Analysis
- Developing contracts and agreements
- Onboarding providers
- Final User Acceptance Testing (UAT)
- Distribute system to hospitals and training
- Finalising case lists to be outsourced
- Securing implementation budget

Maintenance & Future Planning

- Continue monitoring and management of risks
- Improvement of implementation based on feedbacks
- Analysing financial data for future planning
- Planning for expansion of hospital services outsourcing
- Developing innovative payment mechanism for hospital service outsourcing



DEC 23

SERVICES AND PROCEDURE/TREATMENT INVOLVED

Cardiothoracic

- Adult Open-Heart Surgery
 - Coronary artery bypass graph (CABG)
 - Valve Replacement (AVR/ MVR)
- Paediatrics
 Open-Heart
 Surgery
 (Congenital)

Cardiology

- Cardiology Investigation
 - Holter
 - Echocardiogram
 - Exercise Stress Test
 - Dobutamine Stress
 Test
- Cardiology
 Intervention
 - Coronary Angiogram
 - Percutaneous Coronary Intervention (PCI)
- Paediatrics Cardiology (congenital)

Radiology

- · CT Scan
- · MRI
- MRI Cardiac
- Ultrasound

Nephrology

AtrioVenousFistulaSurgery(AVF)

Nuclear Medicine

PET Scan

OUTSOURCING PROCESS OVERVIEW



MAIN OUTSOURCING PROCESS

PRICE SETTING via RFP & COSTING

Request for Proposals (RFP) from Private Hospitals



Analysis Proposed
Prices & Specifications
& Compare with MOH
(& Private) Costing



Pre-determine Prices & Spec.



DIGITALISED OUTSOURCING PROCESS



Qualified providers inform maximum capacity (Digitalised Market-Place)



Pre qualify & contract with interested private hospitals



Engage with Private Hospitals



Zoning:

Optimise <u>competition</u> (multiple private hospitals) & **patient** <u>accessibility</u> (not too far)



Allocation:


Allocate equally to qualified & within zone private hospitals (not exceeding max cap)



Start Service
- MOH Specialist identify
patients and refer
- Private Hosp arrange

 Private Hosp arrange appointment, provide services & claim

RAJAH PERHUBUNGAN UNTUK HSOP



REQUEST FOR PROPOSAL

- Introduction
- RFP Components








INTRODUCTION





Objective: A Request for Proposal (RFP) is a document that outlines the requirements and specifications for a project.

Purpose: Facilitates a structured procurement process by inviting vendors to submit proposals for fulfilling a specific need.

IMPORTANCE OF RFP IN PROCUREMENT



Ensures a fair and competitive bidding process.



Enables objective evaluation and market analysis of vendor proposals.




Mitigates risks by defining project expectations clearly.



Enhances transparency and accountability in procurement.



RFP PROCESS & PLANNING





RFP COMPONENTS





Scope of Work



Requirement



Pricing



Provider Information



Submission Guidelines



Terms & Conditions



1. INTRODUCTION AND BACKGROUND



Overview

Clearly state the purpose of the RFP, outlining the specific goals and objectives that the organization aims to achieve through the procurement process.



Company Information

Provide a brief overview of our company, including its mission, vision, and key functions. This helps bidders understand the context in which the project is taking place.



2. SCOPE OF WORK

Outlines the specific tasks, services, and responsibilities that the selected vendor or service provider will be required to perform under the proposed agreement.

It provides a detailed and comprehensive description of the work to be undertaken to achieve the objectives outlined in the Request for Proposal (RFP).

This section serves as a roadmap for the successful execution of the project or services.



3. REQUIREMENT











Staffing Requirements **Equipment Requirements**

Software Requirements

Medicine

Procedure



4. PRICING

The Private Provider is expected to offer the procedural cost as a **bundled package**. In this context, a **bundle fee** entails that the price incorporates all associated services.

It is not based on individual fees for each service; instead, a fixed fee is paid upon completion of the procedure, irrespective of any variations that may occur during the course of treatment.

A bundled package provides a comprehensive and transparent pricing model, simplifying the billing process by encompassing all necessary services under a single, predetermined cost and allow the private provider to optimise the necessary services providing to patients in order to deliver quality health care services with good efficiency.



5. PROVIDER INFORMATION

HQ BRANCH

Provider Name

Provider Experience

Provider Address

References

Person-In-Charge

CKAPS License

Type of services

Branch Name

Experience

Address

References

Person-In-Charge



6. SUBMISSION GUIDELINES

- The proposal should be organized in a clear and logical manner, with each section clearly labeled. The Provider should also ensure that the proposal is complete and addresses all the requirements in the RFP.
- It should include all the necessary information as outlined in the RFP, including details below.

Submission Check-list

PROTECTHEALTH

- Please make sure your submission is complete, and all documents listed below are submitted as electronic copy to hsop_rfp@protecthealth.com.my.
- Submission consists of the following:
 - 1. Request for Proposal (RFP)
 - 2. Company Profile
 - 3. Other supporting documents
- Any response received after this date may be considered non-responsive, and ProtectHealth would not be obligated to engage your organization any further in our RFP process.
- All responses and supporting documentation shall become the property of ProtectHealth Corporation and will not be returned.

7. TERM & CONDITIONS

Section	Description			
Payment Terms	After the procedure is done and whole service is completed (including post-procedure follow-ups and referral as stipulated), the payment will be made within 3 month of complete submission of claims			
Contract Length	July to December 2024			






HOSPITAL SERVICES OUTSOURCING PROGRAMME: NUCLEAR MEDICINE

25 July 2024

Request For Proposal (RFP) Components





OVERVIEW

Project Title

 Hospital Services Outsourcing for Nuclear Medicine Procedures

Project Description

 General information on the imaging focus and brief information on the provider.

Project Timeline

 The project aims to have the first patient visit on August 2024.



SCOPE OF WORK – POSITRON EMISSION TOMOGRAPHY (PET) SCAN

Detailed Description

Whole body PET-CT & Total Body PET-CT

Patient Selection/Eligibility for the Service

Malaysian, focusing on elective/semi-urgent cases.

Potential Volume

• 300

Pre-procedural Care

Consent form and pre-imaging medication

Post-procedural Care



Emergency crisis

REQUIREMENT – PET SCAN

Equipment Needed	List of Equipment (Spec of the equipment)			
	Equipment license (MDA and ATOM)			
	System for maintenance, calibration and quality assurance (QA)			
Staffing Requirements	Physician			
	Nuclear Medicine Technologists			
	Nuclear Medicine Pharmacist			
	Medical Physicist			
	Staff Nurse			
Facility Requirements	Emergency response			
	Nuclear Medicine Department			



REQUIREMENT – PET SCAN

Medication	IV Piriton
	IV Hydrocortisone
	Actrapid insulin (Rapid acting)
	IV Frusemide
	IV Midazolam
Miscellaneous	Drinking water during the up-take procedure and prior to imaging
	The panel provider is responsible for handling radioactive and non- radioactive waste management comprehensively
Reporting Requirements	CD/DVD
	Report within maximum of five (5) working days after the procedure
	Image Archiving and Storage



PRICING

Bundled Package

A **bundle fee** entails that the price incorporates all associated services

A **fixed fee** is paid upon completion of the procedure, irrespective of any variations that may occur during the course of treatment



RFP Submission Guidelines

- The Provider should also ensure that the proposal is complete and addresses all the requirements in the RFP.
- It should include all the required information outlined in the RFP, including details below.
- Submission Check-list
 - Please make sure your submission is complete and all documents listed below are submitted electronic copy via email: hsop_rfp@protecthealth.com.my
 - Submission consists of the following:
 - 1. Filled RFP PDF format for each service
 - 2. Filled RFP Excel format for each service
 - 3. Hospital CKAPs Borang 4 / Borang 7
 - 4. Company / Hospital SSM
 - 5. Cover Letter by CEO confirming the validity of all information provided and nomination of a HSOP Person-in-charge
 - All responses and supporting documentation shall become the property of ProtectHealth Corporation and will not be returned.




TERM & CONDITIONS

Section	Description
Payment Terms	After the procedure is done and whole service is completed (including post-procedure follow-ups and referral as stipulated), the payment will be made within 3 month of complete submission of claims
Contract Length	July to December 2024



ADDITIONAL INFORMATION



Reporting Template



F-18 FDG Reporting Template: Oncology Cases

F-18 FDG PET-CT Reporting Template: ONCOLOGY

Demographics Data	Name:			
	IC:			
	Gender:			
	Address:			
	Height/weight:			
	Past Medical History:			
	Medications:			
Clinical history	Tumour Type:			
	Primary Site:			
	Biopsy result			
	Last treatment should be st	tated (e.g.: chemotherapy, radiotherapy,		
	immunotherapy, GCSF).			
Indications	 Abnormality to be eval 	uated		
	 Specific clinical question 	n (i.e. staging of lung carcinoma, history of		
	colorectal carcinoma w	rith rising CEA)		
Protocol/technique	FBS:			
and procedure	Dose:			
	Site:	Time/uptake time:		
	Type of imaging:			
	Whole body/Total body imaging			
	Brain protocol			
	Bladder protocol			
	Repeat imaging: Y/N	Site and time:		
	Additional drugs:			
	Contrast: Y/N			
	Image reconstruction: e.g. PET/CT images viewed with AC/Q450 MFQS.			
	* Note an explanation of a	ny deviation from standard protocol or special		
	measures patient may have required.			
Findings	Comparison was made with	previous PET-CT dated (if follow up scan)		
	1. Following anatomic site	e – from top to bottom. In each region to begin		
	with significant PET and Ct findings, followed by relevant CT findings			
	and incidental observations.			
	Head and neck			
	Chest/Thorax			
	Chest/Thorax Abdomen and pelvis	:		

	Based on priority or order of importance e.g. TNM format	
	Follows TNM staging classification for the tumour:	
	Dominant findings: findings and pertinent negatives relevant to clinical question i.e. description of primary lesion (T) or dominant sites of recurrent disease Metastases: additional sites of abnormal radiotracer localization to represent nodal and/or extranodal sites of metastatic disease Other abnormal PET findings: inflammatory or infectious process benign FDG avid disease etc. Incidental CT findings: lung nodules without FDG uptake, AAA, renal masses, etc. Normal physiologic FDG uptake: brown fat, prominent muscle or intestinal uptake Combination of Priority and Anatomic Site	
	* Optional to use one of the formats from 1 – 3 (anatomic, priority or	
Conclusions	combination) • Brief and concise	
Correlations	Answer the clinical question	
	Give a precise diagnosis	
	 When a precise diagnosis is not possible; a clear and organized differential diagnosis should be given 	
	 Discussion of additional imaging studies or follow up, if this would aid in the arrival at the correct diagnosis 	
	Consultation remarks (i.e., bilateral adrenal uptake on	
	immunotherapy – to put footnote; blood glucose of 11mmol/L - TRO diabetes; metformin use)	



F-18 FDG Reporting Template: LYMPHOMA Cases

F-18 FDG PET-CT Reporting Template: LYMPHOMA

Demographics Data	Name:			
	IC:			
	Gender:			
	Address:			
	Height/weight:			
	Past Medical History:			
	Medications:			
Clinical Summary	Type:			
	Primary Site:			
	Last treatment should be stated (e.g.: chemotherapy, radiotherapy,			
	immunotherapy, GCSF).			
Indications	Time: Baseline/Interim/End of Treatment/Surveillance/Assessment of			
	recurrence.			
	Baseline scan: It is performed prior to institution of the definitive			
	therapy to provide information about the staging and enable			
	comparison with the subsequent study to facilitate evaluation of			
	treatment response.			
	Interim scan: It is the mid-treatment scan frequently done after the			
	2nd or 3rd cycle of therapy (e.g. ABVD chemotherapy in HL), at a			
	timing just before the start of the following cycle. It is useful to			
	predict the response to the current regime so that early treatment			
	adaptation can be performed.			
	End-of-treatment scan: It is used to evaluate response following the			
	completion of the predefined treatment regime, usually within 6			
	months after treatment.			
	Follow-up scan under watchful-wait strategy: It refers to the follow-			
	up scan which is done i) to monitor persistent thymic uptake, or ii) to			
	assess the equivocal findings on previous PET-CT scan.			
	Surveillance scan: It refers to the follow-up scan which is done i)			
	more than 6 months after completion of the definitive treatment			
	,			
	with the purpose of screening to ensure remission, or ii) to screen for			
	relapse after achieving complete remission, where there is no			
	suspicious biomarker of imaging finding.			
Protocol/technique	FRS:			
and procedure	Dose:			
and procedure	Site: Time/uptake time:			
	Type of imaging:			
	"			
	Whole body/Total body imaging Resis protects!			
	Brain protocol Bladdon protocol			
	Bladder protocol Repeat imaging: Y/N Site and time:			
	Additional drugs:			

	Contrast: Y/N				
	Image reconstruction: e.g. PET/CT images viewed with AC/Q450 MFQS.				
Findings	Mediastinal blood pool (SUVmax), Liver (SUVmax)				
	Comparison was made with previous PET-CT dated (if follow up scan)				
	Primary disease/lesion.				
	Nodal (Site, Size, SUVmax, Deauville score) follow list in indications.				
	Head : Occipital/ Mastoid/ Parotid				
	Neck : Cervical – superficial and deep)				
	Thorax : Hilar/Lobar/Segmental/Subsegmental, Mediastinal				
	Abdomen : Paraaortic/Aortocaval/Paracaval				
	Coeliac/Superior/Inferior Mesenteric				
	Hepatic/Splenic/Gastric				
	Paravertebral/Para-oesophageal				
	Retrocrural				
	Common Iliac (right/left)				
	Internal Iliac (right/left)				
	External Iliac (right/left)				
	Arms : Superficial				
	: Deep: Axillary (Level I, II, III)				
	Lower : Inguinal (Superficial/Deep)				
	Limbs Popliteal				
	Linus Popiiteai				
	3. Spieen				
	4. Extranodal:				
	CNS				
	Head & : Orbit				
	Neck Nose/Paranasal sinuses				
	Thorax : Pulmonary				
	Pleural/Pericardial				
	Thymus				
	Breast				
	Abdomen : Stomach/Small Intestine				
	Liver				
	Kidney				
	Adrenal				
	Genital				
	Cutaneous				
	Bone				
	5. Artefacts				
	6. Non-oncological incidental findings				
	* Optional to use hybrid/anatomical reporting in NHL/HL.				
	I				

e.g. Hypermetabolic/FDG avid lymphomatous disease at the (optional
to include Lugano/Ann Arbor classification)
Therapy response/comparison: Complete MR/ Partial MR/Stable MR/
Progressive MR

Note

- Measurement of tumour size (on CT): suggestion for bidimensional (including the large diameter: RECII 2017
- 2. Measurement of nodal size (on CT): Uni-dimensional short axis





Consent & Checklist



PET-CT Imaging Request Form Example

			Version 1.1	Version 1.1
				Clinical Indication:
	HOSPITAL UMUM SARAIM JABATAN PERUBATAN NUKL JALAN HOSPITAL 93586 KUCHING, [Pe] Tell : 082-276666 No. faxs Extrounder 5111 Directifie:	SARAWAK	8 8	Baseline scan for: Staging in newly diagnosed malignancy or Restaging in proven recurrence or Pre-treatment scan for response assessment
	Email: nuclear medicine sgh@gm	nail.com		Interim scan for early response prediction after starting a short course therapy or restaging after recording the response the treatment plan
	naging Request Form		Urgent	 End of treatment scan within 6 months, please specify: (e.g. surgery/chemotherapy/chemoradiotherapy/ SIRT/cryo- or radiofrequency ablation etc.)
Put a tick (v) in the relevant checkbox . Put a de	assessment of the impact of PET/CT scan. All columns in () in the column if the information is not availab or is properly filled up and all the required informatio	le.	Non-urgent Next clinic date:	Second look scan under watchful-wait strategy for earlier equivocal finding (e.g. thymic uptake), please state the previous PET-CT study date:
Patient's Name:		Gender:	Ethnic Group:	□ Evaluation for recurrence based on clinical, tumour biomarker and/or other equivocal imaging and to proceed for
IC No.: Address:	Date of Birth: A	ge: Co	ntact No.:	restaging if recurrence is detected Surveillance scan for screening patient in remission and not on any anti-cancer treatment
Address: City/Town:	Postcode:	State:		Surveillance scan for screening patient in remission and not on any anti-cancer treatment Assessing treatment efficacy following prolonged systemic treatment, with intention to change the therapy upon
Eligibility for subsidize PET/CT:Yes / No				disease progression
ocial workerreferral: Yes / No				Tissue characterization or assessment of tumour heterogeneity for high aggressive phenotype.
Relevant medical history: Diabetic Claustrophobic Drug alleigy Pregnant	Yes Insulin Regime: Oral Hypoglycemic No No Yes No Yes Medication: Yes No LMP:	Agent		Please specify further: □ To differentiste benign and malignant lesion in patient not known to have cancer (e.g. SPN) □ Identification of biopsy site for cancer □ For targeted radionuclide therapy/theranostic planning e.g. non iodine-avid thyroid cancer, FDG-avid NET or FDG-avid prostate cancer etc.)
Primary site of disease:				Other:
Head & neck tumour Colorectal cancer Sarcoma Other	Lung cancer Oesopha Ovarian cancer Cervical o Unknown 1° with metastatic cervical no		Gastriccancer Lymphoma histopathology exam.)	Referring consultant/specialist: Name : Signature: Title : Tel. No. :
Assessment based on (please fill up all Clinical history and current relevant s	applied): ymptoms: Please use additional sheet(s),	attached as appen	dix if required:	Hospital
Clinical examination:				
Surgery/Histopathology:	(Da	ote)		
Imaging (e.g. CT/MRI/PET-CT):	(Do	ote)		
Other (e.g. CEA, CA-125, CgA):	(Do	ote)		
Freatment Surgery: Radiofherapy:	Date: Date:		Site: Site:	
Chemotherapy: Others:	Date: Date:		Regime:	Page 2 of 2



PET-CT Imaging Consent Form

	Guardian / Name of Person with Legal Responsibility)	
have been given sufficient info		to make an informed decision an
consent to the PET / CT proces	dures. I have also been informed about the potential ris	sks and side effects of procedures:
Radiopharmaceutical Risks		
i. Expose your fetus to radio	ation if you are pregnant.	
 Expose your child to radio 	ation if you are breastfeeding within 24 hours post F-1	8 FDG injection.
iii. May trigger a major allerg	ic reaction, in rare instances.	
Patient Requiring Contrast As	gent	
I also authorize the designated	Hospital Staff Nurse and Nuclear Medicine Radiograph	er to inject me with the contrast age
Specifically, I have been informe	ed about potential risks and side effects of the contrast	agent (nausea, vomiting, shortness
breath, allergic reaction and cor	ntrast induced renal impairment).	
Patient's Initial		
For Female Only		
I am currently NOT prognant a	and have no reason to suspect that I am pregnant.	
LWP.	Patient's Initial	
	CONFIRMATION	
, the undersigned consent to:	SOMMERATION	
	/CT scan as described above	
ii. The administration of contri		
Patient's Name :	Guardian's Name :	
ICNo :	IC No :	
Date :	Date :	
Signature / Ti	humbprint	Sgnature
Signature / Ti Winess's Name :	humbprint Doctor's Name :	Signature
		Signature
Witness's Name :	Doctor's Name	Signature
Witness's Name :	Doctor's Name	Signature



DOCUMENTATION & VIDEO

The RFP documents are accessible for download starting today through the website https://protecthealth.com.my/hsop/

Additionally, recording videos will be made available for your reference.



SUBMISSION DAY

Thursday, 2 August 2024, please make sure to deliver by digital copy to hsop_rfp@protecthealth.com.my before 4.00pm.



OPEN DAY 29 July 2024

Virtual

- Platform: Zoom
- 2.30pm 3.30pm
- Link for registration will be available online in ProtectHealth website (https://zoom.us/j/97001000203?pwd=wBaGrJ5XuzQ5yaxC4AKRokKgQ3D3yP.1)





THANKYOU

